Predictive value of CD8/FOXP3 ratio combined with PD-L1 expression for radiosensitivity in patients with squamous cell carcinoma of the larynx receiving definitive radiation therapy.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 32808399.
- Also identified by DOI 10.1002/hed.26416.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Little is known about immune-related radiosensitivity in patients with squamous cell carcinoma of the larynx (SCC-L) treated with radiation therapy (RT). We retrospectively reviewed 91 patients with SCC-L treated with RT or chemoradiation therapy and performed immunohistochemical examination to analyze PD-L1 level on tumor cells, CD4<sup>+</sup> tumor-infiltrating lymphocytes (TILs), CD8<sup>+</sup> TIL, and FOXP3<sup>+</sup> TIL using pretreated biopsy specimens. The association between these immune-related parameters and radiosensitivity was evaluated. Multivariate analyses showed that high CD8/FOXP3 ratio combined with negative PD-L1 expression was an independent and significant favorable predictive factor for local control, compared with the other groups. We showed that high CD8/FOXP3 ratio combined with negative PD-L1 expression might be a useful biomarker of radiosensitivity in patients with SCC-L receiving definitive RT. We propose that coassessment of CD8/FOXP3 ratio and PD-L1 expression level in tumor cells can help predict potential radiosensitivity in patients with SCC-L.
Medical subject headings
- B7-H1 Antigen
- Head and Neck Neoplasms